What non‑Z‑drug pharmacologic options are available for treating insomnia?

Non-Z-Drug Sleep Aids for Insomnia

For chronic insomnia requiring pharmacotherapy, the strongest evidence-based non-Z-drug options are suvorexant (dual orexin receptor antagonist) for sleep maintenance, ramelteon (melatonin receptor agonist) for sleep onset, and low-dose doxepin (3-6 mg) for sleep maintenance. 1

First-Line Non-Z-Drug Pharmacologic Options

Dual Orexin Receptor Antagonists (DORAs)

• Suvorexant is recommended for sleep maintenance insomnia with weak GRADE recommendation based on low-quality evidence 1
• Newer DORAs include daridorexant (8-hour half-life, demonstrated 12-month efficacy) and lemborexant 2
• Key advantage: These inhibit wakefulness rather than induce sedation, with no evidence of rebound insomnia, withdrawal, or abuse potential 2
• Particularly suitable when avoiding sedative-hypnotics is a priority

Melatonin Receptor Agonists

• Ramelteon (8 mg) is recommended for sleep onset insomnia 1
• Weak recommendation but favorable safety profile
• Note: Standard melatonin (2 mg) is NOT recommended due to insufficient evidence 1
• Exception: Prolonged-release melatonin may be considered in adults over 55 years 1

Low-Dose Tricyclic Antidepressant

• Doxepin (3-6 mg) is recommended for sleep maintenance insomnia 1
• Demonstrated sustained sleep improvement with safety profile comparable to placebo 3
• This is a much lower dose than used for depression (typically 75-300 mg)

Benzodiazepines (Non-Z-Drug Alternative)

While technically sedative-hypnotics, if you must use this class but want to avoid Z-drugs:

• Temazepam (15 mg): For both sleep onset and maintenance 1
• Triazolam (0.25 mg): For sleep onset only 1
• Critical caveat: Associated with increased risk of dementia, fractures, major injury, cognitive/behavioral changes, and driving impairment, particularly in older adults 4

Medications NOT Recommended

The following have weak recommendations AGAINST use due to insufficient evidence or unfavorable benefit-to-harm ratios 1:

• Trazodone (despite widespread off-label use)
• Tiagabine (anticonvulsant)
• Diphenhydramine (OTC antihistamine)
• Standard melatonin (2 mg)
• L-tryptophan
• Valerian
• Amitriptyline, mirtazapine, quetiapine (limited evidence despite common use) 5

Clinical Decision Algorithm

Step 1: Determine insomnia subtype

• Sleep onset difficulty → Ramelteon
• Sleep maintenance difficulty → Suvorexant, lemborexant, daridorexant, or low-dose doxepin
• Both → Daridorexant or temazepam (if benzodiazepines acceptable)

Step 2: Consider patient-specific factors

• Older adults (>65 years): Prioritize suvorexant or doxepin; avoid benzodiazepines 3
• Abuse/dependence concerns: DORAs preferred (no abuse potential) 2
• Comorbid depression: Consider doxepin (has antidepressant properties at higher doses)
• Need for long-term therapy: Daridorexant has demonstrated 12-month efficacy 2

Step 3: Avoid common pitfalls

• Do not use standard-dose tricyclics (amitriptyline, trazodone) as first-line—insufficient evidence 1
• Do not recommend OTC antihistamines—lack of efficacy data and anticholinergic burden 1
• Do not prescribe standard melatonin supplements—ineffective per guidelines 1

Important Safety Considerations

All pharmacologic interventions carry risks of cognitive and behavioral changes, including driving impairment 4. Observational data suggest hypnotics may be associated with increased dementia risk, fractures, and major injury, though causality is uncertain 4. The FDA specifically advises dose reduction in women and older adults 4.

Context: Cognitive Behavioral Therapy Priority

All patients should receive CBT-I as initial treatment before or alongside pharmacotherapy 1. This is a strong recommendation based on moderate-quality evidence. Pharmacotherapy should be reserved for patients unable to participate in CBT-I, those with persistent symptoms despite CBT-I, or as temporary adjunct therapy 1.

The evidence quality for most pharmacologic agents remains low to very low, with most trials being small, short-term, and industry-funded 4, 1. Long-term efficacy and comparative effectiveness data are lacking across all drug classes 4.